Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

Sitala Bio Ltd. has divulged complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, ...

The FDA approved iptacopan for treatment of adults with paroxysmal nocturnal hemoglobinuria. Iptacopan (Fabhalta, Novartis) is an oral selective complement factor B inhibitor designed to be given as ...

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, ...

Expert panelists evaluate results regarding complement inhibitor trials for utilization in PNH management. Several complement inhibitors have been approved since eculizumab, including ravulizumab, a ...